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Comparative global immune-related gene profiling of
somatic cells, human pluripotent stem cells and their
derivatives: implication for human lymphocyte
proliferation
Chia-Eng Wu1,9, Chen-Wei Yu2,3,9, Kai-Wei Chang4, Wen-Hsi Chou2,3, Chen-Yu Lu3, Elisa Ghelfi5,
Fang-Chun Wu2,3, Pey-Shynan Jan2,3, Mei-Chi Huang3, Patrick Allard6, Shau-Ping Lin4,7,8, Hong-Nerng Ho1,2,3
and Hsin-Fu Chen2,3
Human pluripotent stem cells (hPSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), represent potentially
unlimited cell sources for clinical applications. Previous studies have suggested that hPSCs may benefit from immune privilege
and limited immunogenicity, as reflected by the reduced expression of major histocompatibility complex class-related molecules.
Here we investigated the global immune-related gene expression profiles of human ESCs, hiPSCs and somatic cells and
identified candidate immune-related genes that may alter their immunogenicity. The expression levels of global immune-related
genes were determined by comparing undifferentiated and differentiated stem cells and three types of human somatic cells:
dermal papilla cells, ovarian granulosa cells and foreskin fibroblast cells. We identified the differentially expressed genes CD24,
GATA3, PROM1, THBS2, LY96, IFIT3, CXCR4, IL1R1, FGFR3, IDO1 and KDR, which overlapped with selected immune-related
gene lists. In further analyses, mammalian target of rapamycin complex (mTOR) signaling was investigated in the differentiated
stem cells following treatment with rapamycin and lentiviral transduction with specific short-hairpin RNAs. We found that the
inhibition of mTOR signal pathways significantly downregulated the immunogenicity of differentiated stem cells. We also tested
the immune responses induced in differentiated stem cells by mixed lymphocyte reactions. We found that CD24- and
GATA3-deficient differentiated stem cells including neural lineage cells had limited abilities to activate human lymphocytes. By
analyzing the transcriptome signature of immune-related genes, we observed a tendency of the hPSCs to differentiate toward an
immune cell phenotype. Taken together, these data identify candidate immune-related genes that might constitute valuable
targets for clinical applications.
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INTRODUCTION
Derivatives of human pluripotent stem cells (hPSCs), including
embryonic stem cells (ESCs) and induced PSCs (iPSCs), are a
potentially unlimited source of cells with considerable
promise for basic research and organ transplants. However,
the immunogenicity of these cells remains a major hurdle that
precludes their clinical application. Over the past decade,
several reports have provided in vivo and in vitro evidence of
reduced immunogenicity and immune privilege of ESCs, iPSCs
and their derivatives.1–5 These phenomena may reflect inherent
characteristics of PSCs, including the lower expression of
major histocompatibility complex class I (MHC-I), MHC-II
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and natural killer (NK) cell receptor ligands.2,5,6 In
addition to reduced MHC expression levels, an alteration of
immune-related and immune privilege genes in PSCs may also
be associated with their distinct immunogenicity.5 Accordingly,
various strategies have been proposed to take this hypothesis
into account, such as the banking of MHC-matched stem cells,
establishment of ESCs by nuclear transfer-derived embryos and
derivation of patient-specific iPSCs.7,8
Recently, the discovery of hiPSCs that are reprogrammed
from somatic cells by transduction of the factors Oct4, Sox2,
Klf4 and c-Myc has revolutionized the stem cell field and
demonstrated the potential to evade immune rejection after
transplantation.9 Although the use of autologous hiPSCs has
emerged as a new prospect to overcome immunogenicity
caused by MHC mismatching, significant immunogenicity of
teratomas derived from syngeneic iPSCs, but not ESCs, was
reported in a mouse model.10 Moreover, reprogramming
defects and the genetic instability of iPSCs are reported to lead
to the expression of genes such as Zg16, Hormad1, Cyp3a11,
Retn and Lce1f and the induction of immunogenicity.10,11
Evidence shows that iPSCs derived from CD34+ hematopoietic
stem cells maintain greater genomic stability than do terminally
differentiated somatic cells, with relatively few somatic
mutations compared with other somatic-derived iPSCs.12
However, the clinical applicability of potentially reduced
immune responses in differentiated cells derived from CD34+
hematopoietic stem cell-iPSCs on remains questionable. These
reports suggest that in spite of the limited immunogenicity of
differentiated cells from iPSCs, which might be similar to the
differentiated cells from ESCs, the specifically differentiated
cells from iPSCs could still induce certain immune reactions.
The mammalian target of rapamycin (mTOR) is a widely
expressed serine/threonine protein kinase that has emerged as
an important regulator of immune function, including T-cell
activation, differentiation and function.13 In addition, the Akt/
mTOR signaling pathway has been identified as a key mediator
of human immunity and may be leveraged as a therapeutic
strategy using rapamycin.14,15 Although the immunosuppres-
sive effects of this agent during cell transplantation have been
well documented, the ensuing transcriptome signatures and
biological functions of rapamycin following stem cell trans-
plantation remain incompletely understood. In the present
study, we compare global immune-related gene expression
patterns among undifferentiated stem cells, stem cell derivatives
and their respective parental somatic cells of origin. In
addition, we examine the role of the mTOR pathway in
regulating the immunogenicity of hPSC-derived cells.
MATERIALS AND METHODS
Pluripotent stem cell culture, differentiation and reagents
Several hPSCs were used in the present study, including two hESCs:
NTU1 (karyotype 46, XX)16 and H9 cells (karyotype 46, XX; WiCell,
Madison, WI, USA).17 The iGra2 hiPSCs were derived from
reprogrammed human granulosa cells5 and the iCFB hiPSCs were
derived from reprogrammed human foreskin fibroblasts by our
group.18 The CBiPSCs (CB: cord blood) were generated using human
cord blood-derived CD34+ progenitors with seven episomally expressed
factors (catalog number A18945, Life Technologies, Taipei, Taiwan, R.
O.C.).19 Thus, three types of somatic cells were used for hiPSC
generation and were used as somatic cell controls, including human
primary dermal papilla cells (adult human origin), human primary
foreskin fibroblast cells (parental cells of iCFB iPSCs; adult Taiwanese
male foreskin) and human primary granulosa cells (parental cells of
iGra2 iPSCs; adult Taiwanese female luteinized granulosa cells). Human
granulosa cells were obtained from ovarian follicular aspirates during
oocyte retrieval in in vitro fertilization programs conducted in the
National Taiwan University Hospital. Culture protocols of pluripotent
stem cells were modified as previously described.4,16,20,21 Briefly, early-
passage hPSCs were used for all experiments. The cells were con-
tinuously maintained on murine embryonic fibroblast feeders using
serum-free medium (ReproCELL ES cell medium, Kanagawa, Japan).
The cells were split weekly using 30-gauge insulin needles (Terumo
Syringe, Tokyo, Japan) as previously described.16,20,22 For in vitro
differentiation, colony pieces were cultured on gelatin-coated dishes
without murine embryonic fibroblast and maintained in complete
culture medium (DMEM-based medium (Gibco, Waltham, MA, USA
and Stembo Bioscience, La Mirada, CA, USA) supplemented with 15%
fetal bovine serum (Gibco), 200 mM glutamin (Invitrogen, Waltham,
MA, USA), 10 mM non-essential amino acids (Invitrogen), 100 mM
sodium pyruvate (Invitrogen) and 1% antibiotic-antimycotic (Invitro-
gen). The medium was refreshed every 3 days and the cells were
harvested on day 15 after differentiation. The complementary (c)-DNA
microarray was undertaken in undifferentiated NTU1 hESCs, undiffer-
entiated iCFB hiPSCs, 15-day differentiated NTU1 cells, differentiated
iCFB cells and somatic cell controls of primary dermal papilla cells,
primary foreskin fibroblast cells and primary granulosa cells. The
neuroectodermal sphere formation was performed as previously
described.23 Briefly, embryoid body formation was generated from
hESC H9 cells for 4 days in serum-free ReproCELL ES cell medium and
then transferred to N2 medium for 3 days to form neuroectodermal
sphere, then cultured in Matrigel for 18 days. The use of human cells
was approved by the Institutional Review Board of Academia Sinica and
the Ethical Committee of National Taiwan University Hospital.
Informed consent was obtained from all subjects.
RNA extraction, cDNA preparation and qPCR
Total RNA was harvested by Trizol reagent (Invitrogen) following the
manufacturer’s instructions. Reverse transcription was performed
using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific,
#L1642, Waltham, MA, USA). Briefly, 1–10 μg of total RNA was
treated with 1 μl of 10× DNase buffer and 1 μl of amplification grade
DNaseI in a 20 μl reaction. The reaction was terminated by the
addition of 1 μl of Dnase stop buffer (Promega, M6106, Madison, WI,
USA). Reverse transcription was performed at 25 °C for 10 min, 50 °C
for an hour and the reaction was terminated by incubating at 85 °C for
5 min. cDNA samples were then aliquoted and stored at − 20 °C.
Quantitative PCR (qPCR) reaction was performed on 1× EvaGreen
reagent (Biotium, Fremont, CA, USA, catalog number 31014); 1 μl of
diluted cDNA and 100 μM selected primers (IDT, San Jose, CA, USA,
Supplementary Table S1) were used at 2 μl in 20 μl of qPCR reaction.
The qPCR procedure was initiated by 3 min at 95 °C, followed by 40
cycles of 15 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. The expression
level of the target genes was calibrated by GAPDH, and the data were
analyzed using the ABI 7500 Fast Real-Time PCR system. Quantifica-
tion of all samples by the software was calculated from the CT and
relative fold changes were calculated using the 2−ΔΔCT.24
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Immunoblotting and flow cytometry
Cells were lysed in RIPA buffer (radioimmunoprecipitation assay
buffer, Darmstadt, Germany) supplemented with ProBlock Gold
phosphatase inhibitor cocktail (Gold Biotechnology, Inc., St Louis,
MO, USA). Immunoblot analysis was performed as previously
described.25 All primary antibody incubations were performed at 4 °
C overnight at the following dilutions: mouse monoclonal anti-CD24
(eBioscience, San Diego, CA, USA), 1:250; mouse monoclonal
anti-GATA3 (Thermo, The Thermo Fisher Scientific Inc., Waltham,
MA, USA), 1:100; rabbit polyclonal anti-mTOR (ab2732, Abcam,
Cambridge, MA, USA), 1:500; mouse monoclonal AKT (ab32505,
Abcam), 1:1000; rabbit monoclonal pAKT (ab81283, Abcam), 1:1500;
mouse monoclonal pS6 (Thermo), 1:500 and mouse monoclonal
anti-β-actin (Thermo), 1:10 000. For CD24 flow cytometric analysis,
anti-CD24 was used in a 1:20 dilution.
Teratoma formation, immunohistochemistry and
immunofluorescence analysis
Forming teratoma from human PSCs was performed as previously
described.26 Immunohistochemistry and immunofluorescence were
performed on formalin-fixed, paraffin-embedded teratoma sections
and differentiated stem cells as previously described.27 Briefly, all
primary antibody incubations were performed overnight at 4 °C.
The primary antibodies were used at the following concentrations:
mouse monoclonal anti-CD24 (Thermo), 1:10; mouse monoclonal
anti-GATA3 (Thermo), 1:50; goat monoclonal anti-SOX17 (R&D
System), 1:10; goat monoclonal anti-brachury (R&D System,
Minneapolis, MN, USA), 1:10; rabbit monoclonal anti-beta III tubulin
(ab18207, Abcam), 1:500. For teratoma section staining, antigen
retrieval was performed by microwave heating for 10 min with
10 mM sodium citrate (pH 6). Differentiated stem cells were fixed in
4% PFA and permeabilized in 0.5% Triton X-100. Six to eight images
of the samples were randomly selected and captured at × 400
magnification for quantification by a blinded investigator (C-EW).
Complementary DNA microarray and ingenuity pathway
analysis
First, 10 μg total RNA was used for cDNA synthesis and further
biotin-labeled cDNA hybridization probe generation. The
transcriptome profiling was analyzed using an Affymetrix GeneChip
Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA,
USA) by the Microarray Core Laboratory of the National Health
Research Institutes of Taiwan. All samples used fulfilled the criteria of
an OD260/280 ratio 41.9 and an OD260/230 ratio 41.8. The
ribosomal RNA of 28S was greater than 18S by electrophoresis
analysis. The final image files were detected with an Affymetrix
GeneChip Scanner 3000, and the initial DAT files were processed by
Affymetrix GeneChip Operating Software to generate the raw signal
intensity CEL files. The raw intensity data were normalized using the
robust multi-array average algorithm of GeneSpring software GX11
(Agilent, Santa Clara, CA, USA). The parameter of each chip was
normalized to the 50th percentile. Based on our previous findings in
an immune chip,5 the 85 selected immune-related gene probes were
adopted from the normalized data. The study groups were compared
to each of the three somatic cell controls. The list of genes obtained
from each comparison was used for unsupervised hierarchical
clustering displayed using Tree View Software. The significant up-
or downregulation of candidate genes was examined by performing
the significant analysis of microarrays.28 The results of Log2 fold
change (FC42) ratios and immune-related gene probe IDs from the
comparison were further submitted to Ingenuity Pathway Analysis
(IPA, Ingenuity Systems, http://www.ingenuity.com/) to identify the
network connections of the genes of interest. The data were also
entered into Gene Ontology terms extraction by applying the Fisher’s
exact test using Babelomics (http://babelomics3.bioinfo.cipf.es/). The
top molecules were generated by IPA, and the results were collected
for integration. Highly up- or downregulated genes in all experimental
groups were listed as specific genes that can be attributed to the effects
of differentiation and cell type.
Microarray raw data were uploaded to Gene Expression Omnibus
(GEO) database (human primary dermal papilla cells referred to
GSE28406-GSM702125, human primary granulosa cells referred
to GSE28406-GSM702129 and human primary foreskin cells referred
to GSE28406-GSM702135). To include more immune-related genes in
the analysis, we collected the top 500 probes with high variance across
the samples, incorporated the Immunome database 29 into the analysis
and compared it with the data using the selected immune-related genes.5
RNA interference
A set of Mission short-hairpin RNAs (shRNAs) human CD24 and a
shRNA control vector targeting Green Fluorescent Protein were
purchased from ORIGENE (Rockville, MD, USA). The shRNA
targeting human GATA3 (5′-CATCCAGACCAGAAACCGAAA-3′)
and CD24 (5′-CTTCTGCATCTCTACTCTTAA-3′) lentiviral shRNA
transfer vectors and the expression vectors encoding viral packaging
proteins were provided by the National RNAi Core Facility, Academia
Sinica, Taiwan. The vectors were co-transfected into HEK293 cells as
described previously.30 Supernatants of HEK293 cells were collected
and used to transduce 15-day differentiated stem cells. Puromycin
(2 ng ml− 1; Calbiochem, San Diego, CA, USA) was added to the
medium for 24 h to enrich transduced cells.
Human peripheral blood mononuclear cell isolation and
culture
Human peripheral blood mononuclear cells (PBMCs) were donated
from healthy volunteers and purified by centrifugation on Ficoll-
Hypaque PLUS (GE Healthcare Life Science, Pittsburgh, PA, USA), as
previously described.5 Briefly, PBMCs were isolated by Ficoll-Paque and
washed three times with DPBS (Gibco). The purified T cells were
maintained in complete culture medium supplemented with 10% fetal
bovine serum and the mixed lymphocyte reaction (MLR) was under-
taken within a week. The ‘T cells’ described in this section were human
PBMCs, and these cells were used as the sources of enriched responder
lymphocytes. For positive controls, T cells were treated with PHA
(5 μg ml−1; Sigma, Irvine KA, MO, USA) and/or allogeneic T cells. All
volunteers involved in this study gave informed consent, and the
procedures followed were approved by the institutional ethics committee.
MLR, carboxyfluorescein diacetate succinimidyl ester and
cell co-cultures
A MLR assay was used to evaluate the stimulating effects of
differentiated stem cells on human T-cell proliferation as previously
described.5 Two hESCs (NTU1 and H9), two hiPSCs (iGra2 and
CBiPS) and syngeneic PBMCs were used as stimulator lymphocytes.
Briefly, 15-day differentiated stem cells were treated with mTOR
inhibitor rapamycin (50 ng ml− 1, Millipore, Billerica, MA, USA) for
24 h. Meanwhile, the differentiated stem cells were transduced with
lentiviruses encoding shRNA for CD24, GATA3 or the shControl. The
differentiated stem cells, including rapamycin-treated and CD24 or
GATA3-knockdown (KD) cells, had their further growth arrested by
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the addition of 50 μg ml− 1 mitomycin C (Sigma) to the medium before
incubating with non-stimulated effector T cells. After 5 days, human
T-cell proliferation was measured by BrdU incorporation (Millipore)
using a chemiluminescence-based T proliferation ELISA kit and CFSE
(eBioscience CFSE) following the manufacturer’s instructions.
Enzyme-linked immunosorbent assay
Total human IL-10 and TGFβ (eBioscience) concentrations were
determined using an ELISA kit according to the manufacturer’s
instructions. The intensity of color developed was measured using a
Beckman Coulter DTX 800 microplate reader at 450 nm optical
density (OD) with correction at 570 nm.
Statistics
Except for the microarray data, all statistical analyses were conducted
using GraphPad Prism (version 6.01, La Jolla, CA, USA). The results
are presented as the mean± s.e.m. from at least three independent
experiments. Statistical significance was determined with the
nonparametric Mann–Whitney U (two-tailed) and one-way analysis
of variance by a blinded investigator (CWY). Po0.05 was considered
statistically significant.
RESULTS
Differential immune-related gene expression between PSCs,
their derivatives and somatic cells
Immune-related gene expression in hPSC lines NTU1 hESCs
and iCFB hiPSCs was assessed by microarray analysis before
and after 15 days of differentiation and compared to the
hiPSCs’ parental somatic cells. In a first round of analysis, we
examined the differential expression of the selected immune-
related genes previously characterized as being expressed in
hPSCs and their derivatives present on the microarray.5
We observed a high number of immune gene expression
differences across samples (Supplementary Figure S1). We
further focused our analysis on 85 immune-related genes
of the top 20 up- and downregulated genes that were
identified in undifferentiated NTU1 hESCs and iCFB hiPSCs
(Supplementary Figure S2A and B) and in 15-day differentiated
stem cells (Supplementary Figure S2C and D) compared to the
hiPSCs’ parental somatic primary dermal papilla cells, primary
foreskin fibroblast cells and primary granulosa cells,
respectively.
Among all 85 immune genes, CD24, PROM1 (CD133) and
TNFSF11 were consistently significantly upregulated, and
IFIT3, IL1R1 and LY96 were consistently significantly down-
regulated in undifferentiated stem cells compared with somatic
cells (Figure 1a). In contrast, in undifferentiated stem cells, the
genes CXCR4, GATA3 and CD133 were consistently
upregulated, and only THBS2 was uniformly downregulated
in 15-day differentiated NTU1 hESCs and iCFB hiPSCs when
compared with somatic cells (Figure 1b). Similar expression
patterns of the immune-related genes were observed
when differentiated hPSCs were compared with somatic cells
(Supplementary Figure S2 and Supplementary Tables S2A–D).
The results therefore show that immune-related genes are
extensively regulated in human stem cells and may correlate
with differential developmental immunogenicity.
Identification of immune-related genes using the immunome
database and IPA analyses
In a second round of analyses, we considered the entire
microarray data set and identified the top 500 probes involving
Figure 1 Venn diagrams show overlapping up- or downregulated genes in (a) undifferentiated stem cells and (b) differentiated stem cell
compared with somatic cells. (c) The heat map shows that 25 immune-related genes in the Immunome database were expressed with high
variance. The enriched GO terms in the 11 resulting clusters are shown. Venn diagram shows overlap with the top variance gene list.
GO, Gene Ontology; iCFBD0, undifferentiated iCFB hiPSCs; iCFBD15, 15-day differentiated iCFB hiPSCs; NTU1D0, undifferentiated NTU1
hESCs; NTU1D15, 15 days differentiated NTU1 hESCs; PDPCs, primary dermal papilla cells; PFCs, primary foreskin fibroblast cells;
PGCs, primary granulosa cells.
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366 genes with high variance between stem cells and somatic
cells (Supplementary Figure S3). We selected the top 200
probes with high variance for analysis (42) using the
Immunome database, which is the state-of-the-art reference
set of genes for systems biology of the human immune system.
Using these criteria, we identified 25 genes from the
Immunome database list that also showed high variance
between somatic cells and hPSCs (Figure 1c). In agreement
with the Immunome database analyses, Gene Ontology
analyses identified a significant over-representation of 11
signaling pathways, including ECM–receptor interaction, focal
adhesion, amoebiasis and TGF-β signaling pathways, which are
all important processes in immune function (Figure 1c and
Supplementary Table S3).
To further investigate the differences in immune-related
genes between somatic cells and hPSCs, the microarray data
were analyzed by IPA to identify significant functional
transcriptomic signatures. In experimental groups of hPSCs
(NTU1 and iCFB cells), THBS4, IDO1 and CR1L
(Supplementary Table S4A) were highly upregulated, whereas
TGFβ2 and TGFβ1I1 (Supplementary Table S4A) were highly
downregulated in undifferentiated stem cells compared with
somatic cells. However, these genes were not significantly
expressed after differentiation for 15 days (Supplementary
Table S4B). In contrast, GATA3 expression was not
significantly expressed in any of the hPSCs compared with
somatic cells but was highly upregulated after 15 days of
differentiation (Supplementary Table S4), suggesting the crucial
role of GATA3 in the development of immunogenicity in
differentiated hPSCs. Various other genes were also associated
with differences between undifferentiated and differentiated
stem cells and somatic cells (Supplementary Tables S5A–D).
Taken together, we identified a list of 11 genes with
immune-related functions that are differentially expressed
between hPSCs, their derivatives and various somatic cell
types: CD24, GATA3, CD133, THBS2, LY96, IFIT3, CXCR4,
IL1R1, FGFR3, IDO1 and KDR. These genes may play
important roles in immunological distinctions and were
therefore selected for further investigation.
CD24 is a downstream target of mTOR in differentiated
stem cells
The Akt/mTOR signaling pathway has been identified as a key
mediator of human immunity and has been leveraged as a
therapeutic strategy in tissue transplantation by using
rapamycin.14,15 To investigate the role of mTOR signaling in
mediating the immunogenic properties of hPSC-derived cells,
we examined the mRNA levels of the 11 immune-related genes
identified via microarray analysis after mTOR signaling
modulation. To this aim, we measured their expression levels
by using quantitative PCR with reverse transcription in
rapamycin-treated 15-day differentiated stem cells. CD24
mRNA was significantly reduced by rapamycin in all
differentiated stem cells, including in NTU1, H9 hESCs,
Figure 2 Alterations in mRNA levels of select genes in control and differentiated stem cells. The relative steady-state mRNA levels were
determined in (a) rapamycin treatment, (c) shCD24 and (d) shGATA3 cells by real-time qPCR. (b) Differentiated stem cells were treated
with rapamycin (50 ng ml−1, Rapa) and LY294002 (50 μM, LY), and cell lysates were analyzed by immunoblotting using antibodies against
total and phosphorylated forms of the signaling molecules CD24, GATA3, AKT, pAKT, mTOR and pS6. Mean± s.e.m. is based on three to
five replicate experiments using different batches of differential stem cells. *Po0.05, **Po0.01 and ***Po0.001. Human ESCs: NTU1
and H9; human iPSCs: CBiPS and iGra. ESCs, embryonic stem cells; mTOR, mammalian target of rapamycin; PSCs, pluripotent
stem cells.
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CBiPSCs and iGra2 hiPSCs compared to vehicle-treated
controls (Figure 2a). Next, we confirmed the role of
Akt/mTOR signaling pathways on CD24 and GATA3 expres-
sion at the transcript and protein levels following treatment
with two pathway inhibitors. Differentiated stem cells were
incubated with rapamycin and LY294002 (a PI3K inhibitor) for
24 h. As expected, phospho-Akt and phospho-S6 levels, but not
total Akt and mTOR levels, were significantly diminished in
rapamycin- and LY294002-treated differentiated stem cells
compared with control cells, which demonstrated the specific
inhibition of Akt/mTOR signaling pathways. Interestingly,
CD24 protein levels were decreased in differentiated
stem cells following treatment with either rapamycin or
LY294002 (Figure 2b and Supplementary Figure S4). In
contrast, GATA3 expression was not reduced by
treatment with rapamycin or the PI3K inhibitor in
differentiated stem cells (Figure 2b). Taken together, these
results indicate that the Akt/mTOR pathway regulates CD24 in
stem cell derivatives.
CD24 and GATA3 regulate immune genes in differentiated
hPSCs
We previously showed that derivatives of hPSCs have the ability
to activate lymphocytes and that different hPSCs demonstrate
distinct MHC expression and immunogenicity.5 As shown
above, CD24 and GATA3 are consistently upregulated in hPSC
derivatives (Figure 1) and may thus play a role in the
regulation of their immunogenicity. To test this hypothesis,
we generated CD24 and GATA3-KD differentiated stem cells
using lentivirus-mediated shRNA transduction and
examined the mRNA expression levels of the 11 differentially
expressed immune genes by quantitative PCR with reverse
transcription. In these experiments, the interleukin receptor
IL1R1 mRNA expression was significantly decreased in all
CD24-KD differentiated stem cells compared to shRNA
control (Figure 2c). The expression of interferon-induced
IFIT3, a negative regulator of cell proliferation, was significantly
decreased in GATA3-KD differentiated stem cells,
whereas CD24 was significantly upregulated (Figure 2d).
Other candidate genes were inconsistently regulated by
CD24 and GATA3 in hESCs and hiPSC derivatives
such as CD133 or KDR (Figure 2c and d). These data
suggest that the reduction in the expression of CD24 or
GATA3 leads to differential regulation of multiple immune-
related genes.
Human T-lymphocyte proliferation is suppressed in CD24
and GATA3-deficient hESC and hiPSC derivatives
To further demonstrate the roles of mTOR, CD24 and GATA3
in the immunogenicity of stem cell derivatives, human T-cell
responses were determined with PBMCs by the MLR assay.
Colony formation assays of human lymphocyte aggregation is
an ex vivo cellular immune assay that occurs between two
allogeneic lymphocyte populations. Syngeneic lymphocyte
reactions used stimulator and responder lymphocytes from
the same donor (Figure 3a). In contrast, stimulator and
responder lymphocytes from different sources with unmatched
HLA (Figure 3b) or following PHA stimulation (Figure 3c),
and differentiated stem cells only (Figure 3d) were used in
allogeneic lymphocyte reactions. To determine suppressive
effects of the mTOR pathway and deficiencies of CD24
and/or GATA3, rapamycin-treated, CD24-KD and/or
GATA3-KD 15-day differentiated stem cells were co-cultured
with PBMCs at varying cell numbers (1× 104 to 1× 105 cells;
Figure 3e–h). MLR analyses showed that 15-day derivatives of
both hESCs (NTU1 and H9) and hiPSCs (CBiPSCs and iGra2
stem cells) induced cell number-dependent proliferation of
responder lymphocytes and were comparable to stimulation by
allogeneic lymphocytes (Figures 3e and 4). These data are in
accordance with our previous report,5 and suggest potential
immunogenicity of differentiated stem cells. In contrast, the
activation of responder lymphocytes was reduced by rapamy-
cin, with significant reductions at distinct cell numbers of
hESCs and hiPSCs (Figure 4a). In particular, significant
decreases were seen with 1× 105 CD24-KD differentiated cells
(Figure 4b) and with similar numbers of GATA3-KD
differentiated stem cells (Figure 4c).
To determine whether rapamycin affects the activation or
function of CD3+CD4+CD25+ human regulatory T cells
(Treg), we screened percentages of Treg cells and expression
levels of IL-10 and TGFβ in rapamycin-treated 15-day H9
hESC differentiated stem cells co-cultured with human T cells.
In these experiments, no significant changes in CD3+CD4+
CD25+ Treg cell numbers were observed after the stimulation
of PBMCs by differentiated stem cells (Supplementary
Figure S5A). However, the production of immunosuppressive
cytokines IL-10 and TGFβ by PBMCs was significantly
increased in response to rapamycin-treated differentiated stem
cells when compared with differentiated stem cell controls
(Supplementary Figure S5B and C). To further demonstrate
whether the rapamycin-mediated immunogenicity suppression
of differentiated stem cells is dependent on CD24 expression or
on the induction of regulatory cytokines, the immune
responses of differentiated stem cells were neutralized with
IL-10 or TGFβ antibodies in the presence or absence of CD24.
Our results indicated that there was no difference in responder
lymphocyte proliferation of rapamycin-treated and
cytokine-neutralized differentiated stem cells compared to
control cells (Supplementary Figure S5D). These results
therefore suggest that both immunosuppressive cytokine
IL-10 and TGFβ-mediated mechanisms are involved in the
differential immune responses of hPSC derivatives. Finally,
synergistic suppressive effects of double CD24/GATA3-KD in
the presence of rapamycin treatment were observed in
differentiated H9 hESCs but not in differentiated CBiPSCs or
NTU1 or iGra stem cells (Figure 5). Taken together, these data
suggest that, consistent with the suppressive effect on rapamy-
cin action, strongly reducing both CD24/GATA3 expression
also resulted in a marked suppression in immunogenicity of
hPSC derivatives.
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Human T lymphocyte proliferation is suppressed in CD24
and GATA3-deficient neural lineage cells
To evaluate whether various lineages of cells derived from
hPSCs expressed CD24 or GATA3, in vitro differentiated stem
cells and teratomas were stained with CD24 or GATA3 in three
germ layers (endoderm, mesoderm and ectoderm). Abundant
CD24 expression was detected in cell surface membrane or
cytoplasm co-localized with beta III tubulin in cells that
differentiated into ectoderm to form the nervous system.
CD24 was also observed in the cells of endoderm both in
teratoma and in vitro differentiated stem cells (Figure 6a).
In contrast, GATA3 was highly expressed in the nucleus and
co-localized with SOX17 in the cells that differentiated into
endoderm to develop the epithelial lining of multiple systems.
GATA3 was detectable in all three germ layers in in vitro stem
cell differentiation whereas the expression was very weak or not
observed in ectoderm of teratoma tissue (Figure 6b). Thus, our
data demonstrate that CD24 and GATA3 are expressed upon
differentiation and canalization into distinct human cell
lineages. To explore the potential clinical cell therapy
applications, rapamycin-treated, CD24-KD and GATA3-KD
neural lineage cells were co-cultured with human PBMCs.
MLR analyses showed that differentiated neural lineage cells
induced cell number-dependent increases in responder
lymphocyte proliferation, thus suggesting the potential
immunogenicity of differentiated neural cells. However, we
observed a significant decrease of responder lymphocyte
proliferation in CD24-KD and GATA3-KD neural cells
compared to control cells (Figure 6c). Surprisingly, no
significant difference was found between the rapamycin-
treated and control cells (Figure 6c). Taken together, our
results indicate that reducing both CD24 and GATA3 expres-
sion resulted in a marked suppression in the immunogenicity
of neural lineage cells derived from hPSCs.
DISCUSSION
Previous studies have suggested that ESCs are immune
privileged in multiple species.1,31–33 However, lineage-specific
derivatives from hESCs may remain recognizable by immune
systems, and allogeneic immune rejection of hESCs by
Figure 3 The colony formation shows human lymphocyte proliferation. Mixed lymphocyte reactions evaluate the actions of (a) syngeneic,
(b) allogeneic (unmatched HLA) lymphocytes, (c) PHA (5 μg ml−1) stimulation, (d) differentiated stem cells only, (e) differentiated stem
cells of shControl, (f) shCD24, (g) shGATA3 and (h) rapamycin treatment. Scale bars, 1000 μm. Human ESCs: NTU1 and H9; human
iPSCs: CBiPS and iGra. ESCs, embryonic stem cells; PSCs, pluripotent stem cells.
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recipients is a major hurdle to clinical application.34 We
previously demonstrated that lower transcript levels of
MHC-I, β2-microglobulin and non-classical MHC-I in undif-
ferentiated stem cells are involved in the differential immune
responses of hESCs compared with those in somatic cells.5
Thus, the development of reprogrammed autologous hiPSCs
from somatic cells provides an efficient potential strategy for
overcoming immune surveillance.9 However, various genes that
are overexpressed in teratomas were originally attributed to the
immunogenicity of syngeneic iPSCs, suggesting that substantial
immune responses remain a drawback of syngeneic iPSC
derivatives.10
To address this issue and investigate hPSC-based strategies
for regenerative therapy, it is necessary to examine expression
profiles of immune-related genes that regulate differential
immune functions in hPSC derivatives. Accordingly, differen-
tiated stem cells are much more suitable for clinical application
as transplants than undifferentiated stem cells. Hence,
comparisons of the expression of immune genes between
differentiated stem cells and somatic cells may facilitate the
understanding of the ensuing therapeutic applications. Our
data demonstrated that several immune-related genes are
differently expressed among human undifferentiated stem cells,
differentiated stem cells, and somatic cells. In particular, several
genes were up- or downregulated in somatic cells only
(including ACTB, CD59, IL6, LGALS1, CD14, CSTA and
HMOX1), in undifferentiated stem cells only (IDO1, SERPINE1
and TGFβ2), or in differentiated stem cells only (GATA3, OLR1
and THBS2). In addition, several immune-related genes were
specifically expressed in hESCs and hiPSCs, including CD24,
CD133 and TNFSF11. Furthermore, these genes were consis-
tently expressed in differentiated stem cells when compared
with various somatic cells. In contrast, the genes IL1R1, LY96
and IFIT3 were specifically and consistently expressed at lower
levels after differentiation than those in somatic cells. These
results suggest that hPSC derivatives remain distinct from
Figure 4 BrdU incorporation of human lymphocytes is measured by co-culture with human pluripotent stem cell derivatives. Proliferation of
human PBMCs is suppressed by co-culture with (a) rapamycin treatment, (b) CD24-knockdown and (c) GAT3-knockdown differentiated
hESCs/hiPSCs. Bar graph represents mean± s.e.m. from four independent experiments. *Significantly different relative proliferation when
compared with syngeneic lymphocytes and control (*Po0.05). Human ESCs: NTU1 and H9; human iPSCs: CBiPS and iGra. PBMCs,
peripheral blood mononuclear cells
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somatic cells in terms of the gene expression that is important
to immune function.35–38
mTOR is a serine/threonine kinase that is present in
mammalian cells as two distinct protein complexes, mTORC1
and mTORC2. mTOR consists of mTOR, mLST8 and Raptor,
which is preferentially inhibited by rapamycin; this
immunosuppressive agent also interferes with mTORC2
activity.39 The mTOR signaling pathway is a key regulator of
cellular metabolism and is specifically involved in anabolic
processes that promote cell growth and proliferation.40
Rapamycin has also been shown to inhibit and stimulate
osteogenesis in mesenchymal stem cells.41,42 However, the
roles of mTOR in differentiation of hPSCs to other lineages
remain unclear. Interestingly, transplant rejection can be
selectively inhibited by low-dose rapamycin treatment.43 Pre-
vious studies have shown that mTOR may regulate the
generation of CD4+ Treg cells.44,45 Moreover, the mTOR
pathway has been implicated in the control of macrophages
and the regulation of CD24+ dendritic cell development.14,46
The glycoprotein CD24 is expressed on the surface of mature
granulocytes, B lymphocytes, and differentiating neuroblasts
and has been shown to regulate B-lymphocyte activation,47
suggesting that CD24 is involved in differential immune
responses. In the present study, we demonstrated that the
Akt/mTOR pathway regulates CD24 in the tested hPSC
derivatives, further indicating by neutralizing immunosuppres-
sive cytokines that the potential immunogenicity of
differentiated stem cells can be ameliorated by rapamycin
treatment following decreased CD24 expression and/or upre-
gulating the immunosuppressive cytokines IL-10 and TGFβ
(Figure 7 and Supplementary Figure S5).
We previously demonstrated the potential immunogenicity
of differentiated stem cells;5 in the present study, an upregula-
tion of GATA3 was consistently observed in both hESC and
hiPSC derivatives, suggesting an active role of GATA3 in
differentiated stem cells. GATA3 has been characterized as an
important transcription factor that binds the T-cell receptor
and has been associated with T-cell development, proliferation,
maintenance and innate lymphoid cell activities.48
Although the functions of GATA3 in hematopoietic lineage
commitment are not completely understood, GATA3
reportedly mediates Notch signaling to promote T-cell
development and inhibit B-cell development.49 In addition to
Th cell lineage, GATA3 is essential at multiple stages of
CD4+ T-cell development and Th2 cytokine responses.50
GATA3 deficiency has been reported to cause embryonic
lethality51 and to suppress the expression of IL-4, IL-6, IL-13
and IL-10.52,53 Treg cells are critical suppressors of immune
responses and maintain self-tolerance,54 and previous studies
have shown that GATA3 deficiency does not affect the thymic
generation of Treg cells as it does in conventional CD4+ T
cells.55,56 In our study, we found that GATA3 is strongly
expressed in differentiated stem cells and observed reduced
lymphocyte proliferation in GATA3-deficient differentiated
stem cells. These findings suggest that the role of GATA3 in
embryonic development may be critical in the regulation of
differential immune responses, in part by harmonizing
different cytokines.
The effectiveness of immune suppressant treatments for
preventing immune rejection has been widely observed.57
However, the side effects related to the toxicity and potential
carcinogenesis are a significant concern in most cell-based
therapies, including hPSC derivatives-based therapies. There-
fore, genetic manipulation is likely to be an efficient and
Figure 5 Human PBMCs proliferation compared to co-culture with
knockdown of CD24 and/or GATA3 in the presence of rapamycin-
treated hESC/hiPSC differentiated cells. The comparative
proliferation of human PBMCs was measured by BrdU incorporation
to hESCs of NTU1, H9, hiPSCs of CBiPS and iGra. Representative
plots and mean results± s.e.m. from four independent experiments
are shown as comparative lymphocyte proliferation (**Po0.01).
Human ESCs: NTU1 and H9; human iPSCs: CBiPS and iGra.
ESCs, embryonic stem cells; PBMCs, peripheral blood mononuclear
cells; PSCs, pluripotent stem cells.
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relatively safe strategy for mitigating these issues by reducing
immune responses of hPSC-derived cells without using
immune suppressants.58 We assessed whether CD24 and/or
GATA3 deficiency leads to reduced immunogenicity of hPSC
derivatives using specific shRNAs. We showed that both
differentiated CD24-KD and GATA3-KD stem cells resulted
in significant reductions in human lymphocyte proliferation.
However, our data also showed that CD24 is upregulated in
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Figure 6 CD24 and GATA3 were expressed in teratoma and the in vitro differentiation cells. (a) CD24 was expressed in the cells of
endoderm (SOX17) and ectoderm (βIII-tubulin). (b) GATA3 was expressed in the cells of endoderm and mesoderm (Brachyury) in teratoma
and ectoderm in in vitro differentiated cells. (c) The CFSE of human lymphocytes is measured by co-culture with human neural lineage
cells. Proliferation of human PBMCs is measured by co-culture with rapamycin treatment, CD24-KD and GAT3-KD cells. Bar graph
represents mean± s.e.m. from three independent experiments. (*Po0.05 and **Po0.01). Scale bars, 20 μm. CFSE, carboxyfluorescein
diacetate succinimidyl ester; KD, knockdown; PBMC, peripheral blood mononuclear cells.
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differentiated GATA3-KD stem cells, which suggests that a
strategy to protect hPSC-derived cells from immune responses
might require double KD of CD24/GATA3. Accordingly, the
immune suppressive effects of double CD24-KD/GATA3-KD
were synergistic in rapamycin-treated differentiated hESCs but
were not observed in hiPSC derivatives. Taken together,
these results suggest that the induction of CD24 by mTOR
could be a critical mechanism that underlies the immunogenic
effects of this pathway. Hence, the immunosuppressive
effects of rapamycin are mediated in part by the inhibition of
CD24 expression. In contrast, the immunogenicity of
differentiated stem cells expressing GATA3 was mediated
by other pathways independent of mTOR, thus warranting
further studies of GATA3-mediated mechanisms of
immunosuppression.
To determine whether various lineages of cells derived from
hPSCs expressed CD24 or GATA3, we took advantage of
the capability of hPSCs to form teratomas and in vitro
differentiation, which contain cells derived from the three
germ layers. CD24 was observed in cells differentiated
into endoderm and ectoderm. By contrast, GATA3 was
strongly expressed in cells differentiated into mesoderm and
endoderm. Previous studies reported that not all iPSC-derived
cells cause immune responses and that the rejection may
only be observed in mesodermal cells.10,11 Our studies
therefore open the door to the further investigation of these
genes and their roles in inducing immunogenicity in specific
tissues.
We leveraged these findings towards clinical application by
using neural lineage cells as a model.23 Our results showed
that CD24 and GATA3 deficiency leads to a significant
immunosuppression in human differentiated neural cells
derived from hPSCs. Interestingly, in contrast to CD24/
GATA3-deficient cells, no significant differences were observed
in rapamycin-treated neural lineage cells. Immunosuppressant
administration, such as rapamycin, could affect neural lineage
cell fate, migration, survival and proliferation, depending on
the treatment time and dosage.59 Taken together, our results
indicate that reducing both CD24 and GATA3 expression
resulted in a marked suppression in immunogenicity of neural
lineage cells derived from hPSCs. Our results suggest that
genetic manipulation of CD24 and GATA3 should be seriously
considered as an immune tolerance strategy to effectively
protect hPSC-derived grafts of the cells from allogenic immune
responses in clinical applications.
In summary, the present data demonstrate that several
immune-related genes including CD24, GATA3, PROM1,
THBS2, LY96, IFIT3, CXCR4, IL1R1, FGFR3, IDO1 and
KDR, are associated with differential immunological
behaviors of somatic cells and hPSC derivatives. Hence,
strategies employing genetic manipulation, such as KD of
CD24 and GATA3, and other genes from the lists may
effectively suppress immune responses after transplantation of
hPSC derivatives. Further studies will be required to
fully characterize the biological significance of these specific
genes on immune responses using an in vivo system of
humanized mice.
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Figure 7 Schematic diagram summarizing immune genetic expression and pathways of hPSC development. Human PSCs are characterized
by immune privilege and expressed CD24, but not GATA3, in the undifferentiated stage. Differential immunogenicity was generated and
demonstrated by human lymphocyte reactions. The expression levels of CD24 and GATA3 were significantly increased in teratoma and
differentiated stem cells of endoderm, mesoderm and ectoderm, respectively. Induction of CD24 by PI3/AKT/mTOR is a critical mechanism
that underlies the immunogenic effects. The immunogenicity of differentiated stem cells expressing GATA3 is mediated by other pathways.
hPSCs, human pluripotent stem cells; mTOR, mammalian target of rapamycin.
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